WebDoctor Encyclopedia

Chronic myeloid & MDS

Chronic myelomonocytic leukaemia (CMML)

Chronic myelomonocytic leukaemia (CMML) is a rare bone marrow cancer of older adults that produces too many monocytes. It shares features of myelodysplastic syndromes and myeloproliferative neoplasms.

Medically reviewed Last reviewed October 17, 2026

What is chronic myelomonocytic leukaemia?

Chronic myelomonocytic leukaemia (CMML) is a rare blood cancer that starts in the bone marrow. It causes the body to make too many monocytes, a type of white blood cell that normally helps fight infection.

CMML sits between two groups of blood disorders. Like myelodysplastic syndromes (MDS), it makes faulty blood cells and can cause low blood counts. Like myeloproliferative neoplasms (MPN), it can produce too many cells and enlarge the spleen. Doctors therefore call it a myelodysplastic/myeloproliferative neoplasm.

CMML mainly affects older people, usually in their seventies, and is about twice as common in men.

Some people have mild disease that stays stable for years and needs only monitoring. Others have more active disease that causes symptoms, and in about 15-30% it changes into acute myeloid leukaemia (AML).

The only treatment that can cure CMML is a donor stem cell transplant, which is suitable for only a minority of patients. Other treatments aim to control the disease and improve quality of life.

1. Key facts at a glance

Feature Details
Type of cancer Myelodysplastic/myeloproliferative neoplasm of the bone marrow
How common About 4 people per million each year
Typical age Median about 70-75; rare under 50
Sex About twice as common in men
Key blood finding Persistent monocyte count of at least 0.5 x 10^9/L, making up 10% or more of white cells
Common gene changes TET2, SRSF2, ASXL1, RUNX1, NRAS, KRAS, CBL
Main treatments Monitoring, transfusions, hydroxyurea, azacitidine or decitabine, donor stem cell transplant
Outlook Very variable; median survival about 2-4 years overall, many years for low-risk disease

2. Types of CMML

Doctors classify CMML by the white cell count and by the number of immature cells (blasts), following the WHO 2022 classification.

Classification Definition What it means
Myelodysplastic CMML (MD-CMML) White cell count below 13 x 10^9/L Mainly low blood counts, anaemia and infections
Myeloproliferative CMML (MP-CMML) White cell count 13 x 10^9/L or more High white cells, large spleen, sweats and weight loss; usually a poorer outlook
CMML-1 Blasts under 5% in blood and under 10% in bone marrow Lower risk
CMML-2 Blasts 5-19% in blood or 10-19% in bone marrow Higher risk of change to AML
AML 20% or more blasts No longer CMML; treated as acute leukaemia

3. Causes and risk factors

CMML develops when a blood stem cell gathers acquired gene changes over time. These changes are found only in the blood cells and are not inherited.

Factor Notes
Age The main risk factor; gene changes in blood cells build up with age (clonal haematopoiesis)
Male sex Men are affected more often
Previous chemotherapy or radiotherapy A small proportion are “therapy-related”
Chemical exposure Benzene and some other chemicals may raise the risk of myeloid blood cancers
Smoking Linked to myeloid blood cancers in general
Family history Rarely relevant; inherited cases are very uncommon

4. How does it look?

CMML is mainly seen in blood and bone marrow tests, but some people have visible signs.

4.1 On the body

Feature What it looks like
Pale skin From anaemia
Bruises and tiny red spots (petechiae) From low platelets
Swollen tummy From a large spleen, felt under the left ribs
Skin lumps or rash Red or purple patches or nodules when CMML cells enter the skin
Swollen gums or lymph nodes Occasionally
Inflammatory signs Joint swelling, rashes or inflamed blood vessels in people with autoimmune features

4.2 Under the microscope

Sample What is seen
Blood film Many monocytes, some immature; abnormal neutrophils with few granules or odd nuclei
Bone marrow Busy marrow with increased monocytes and dysplasia (abnormal-looking cells) in one or more cell lines
Flow cytometry An increase in “classical” monocytes (MO1 fraction above 94%) supports the diagnosis
Cytogenetics Normal in many; trisomy 8, loss of Y or chromosome 7 changes in some

5. Symptoms

Up to a third of people have no symptoms when CMML is found on a routine blood test.

5.1 Common symptoms

Symptom Why it happens
Tiredness and breathlessness Anaemia (low red cells)
Infections Faulty white cells
Bruising and bleeding Low or poorly working platelets; nosebleeds and bleeding gums
Fullness or pain in the left upper tummy Enlarged spleen
Feeling full quickly The spleen presses on the stomach
Night sweats, fever, weight loss More common in the myeloproliferative type

5.2 Less common symptoms

Symptom Notes
Skin lesions Leukaemia cutis, or inflammatory rashes such as Sweet syndrome
Joint pain and swelling Autoimmune or inflammatory conditions occur in about 1 in 5
Bone pain Uncommon
Fluid around the heart or lungs Rare

5.3 When to see a doctor

See a doctor if you have unexplained tiredness, frequent infections, easy bruising, night sweats or weight loss. A simple blood count is the first test. Symptoms that get worse quickly, such as rising fevers or new bleeding, need urgent review.

6. Diagnosis

Test Why it is done
Full blood count Shows persistent monocytosis, and often anaemia or low platelets
Repeat counts Monocytosis must last at least three months
Blood film Looks at the shape of cells and counts blasts
Bone marrow aspirate and biopsy Confirms the diagnosis, counts blasts and checks for fibrosis
Cytogenetics Looks for chromosome changes
Gene panel (NGS) Finds mutations such as TET2, SRSF2 and ASXL1; supports diagnosis and estimates risk
BCR::ABL1 and other tests Rule out chronic myeloid leukaemia and other conditions with similar counts
Tests for other causes Infections, inflammation and other cancers can raise monocytes and must be excluded

Other causes of a raised monocyte count

A high monocyte count is much more often caused by something other than CMML. These causes are ruled out before the diagnosis is made.

Cause Examples
Infections Tuberculosis, endocarditis, some viral and fungal infections
Inflammation Rheumatoid arthritis, lupus, inflammatory bowel disease, sarcoidosis
Recovery of the bone marrow After chemotherapy or a severe infection
Medicines Steroids and growth factor injections
Other blood cancers Chronic myeloid leukaemia, myeloproliferative neoplasms, acute monocytic leukaemia
Other cancers Some solid tumours and lymphomas

7. Risk assessment

Doctors use scoring systems to estimate how CMML is likely to behave.

Score What it includes
CPSS CMML type (CMML-1 or 2), MD or MP type, chromosome risk and transfusion need
CPSS-Mol Adds gene mutations (ASXL1, NRAS, RUNX1, SETBP1) to the CPSS
Mayo molecular model Uses ASXL1 mutation, haemoglobin, platelets, monocyte count and immature cells in blood

Low-risk patients may live many years without treatment. High-risk patients have a greater chance of AML and are assessed early for transplant.

8. Treatment

The choice of treatment depends on the type of CMML, the risk score, symptoms, age and general fitness. Because most patients are older and many have other health problems, the aim is often to control symptoms and keep a good quality of life rather than to cure the disease.

Younger, fitter patients with higher-risk disease should be referred early to a transplant centre, so that a donor search can start while the disease is controlled.

8.1 Overview of options

Treatment Who it is for Notes
Watch and wait Low-risk, no symptoms Regular blood counts
Blood and platelet transfusions Anaemia or bleeding Iron levels are monitored
Erythropoiesis-stimulating agents Anaemia in lower-risk, MD-type disease Injections such as epoetin may reduce transfusions
Hydroxyurea (hydroxycarbamide) High white count, big spleen or sweats in MP-CMML Tablets that lower counts
Azacitidine or decitabine Higher-risk disease or troublesome symptoms Hypomethylating agents; decitabine is also available as a tablet with cedazuridine
Allogeneic stem cell transplant Fit patients with higher-risk disease, usually under about 70-75 The only potentially curative treatment; carries serious risks
Clinical trials Any stage Targeted and new drugs are being studied

8.2 Supportive care

Area What helps
Infection prevention Vaccinations (avoid live vaccines), prompt treatment of fevers
Bleeding Avoid aspirin unless advised; platelet transfusion if needed
Inflammatory problems Steroids or other immune treatments
Fatigue Pacing activities, gentle exercise, treating anaemia

9. Side effects of treatment

Treatment Possible effects
Hydroxyurea Low counts, mouth or leg ulcers, skin changes
Azacitidine or decitabine Low blood counts, infections, nausea, constipation, injection-site redness
Stem cell transplant Severe infections, graft-versus-host disease, organ damage and a risk of death from the treatment itself

Complications that need urgent care

Complication Warning signs
Serious infection Fever, shivering, feeling very unwell; needs same-day antibiotics
Bleeding Nosebleeds that will not stop, blood in urine or stools, many new bruises
Spleen problems Sudden pain under the left ribs or in the left shoulder
Change to AML Rapidly worsening blood counts, rising blasts, new tiredness or infections
Leukostasis Very high white count causing headache, breathlessness or confusion

10. Outlook

Situation Approximate median survival
Low-risk CMML Often more than 5-6 years
Intermediate risk About 2-3 years
High-risk CMML About 1-1.5 years
After stem cell transplant About a third to a half are alive long term
Change to AML Happens in about 15-30% over time

These are averages and depend on the scoring system used. Many people with low-risk CMML die of other causes.

11. Living with CMML

CMML is often a long-term condition. Regular blood tests let the team spot changes early.

Tell your team straight away about fever of 38 C or higher, bleeding, new lumps, or sudden pain under the left ribs, which can mean the spleen is enlarging.

Keep active where you can, eat well and stay up to date with flu, COVID-19 and pneumococcal vaccines. Support from a specialist nurse and patient groups helps people and their families cope with uncertainty.

If you need regular transfusions, ask about your iron levels, as repeated transfusions can lead to iron overload. Keep a record of your blood counts and any treatments, and carry information about your condition when travelling.

12. Frequently asked questions

Question Answer
Is CMML the same as chronic myeloid leukaemia (CML)? No. CML has the BCR::ABL1 (Philadelphia) gene change and is treated with tablets called TKIs. CMML does not
Is it inherited? No. The gene changes happen during life, in the blood cells only
Do I need treatment straight away? Not always. Many people with low-risk CMML only need monitoring
Can it be cured? Only with a donor stem cell transplant; other treatments control the disease
Will it turn into acute leukaemia? Some cases do, especially CMML-2 and high-risk disease, but many never do

13. Questions to ask your care team

  • Do I have MD-CMML or MP-CMML, and is it CMML-1 or CMML-2?
  • What is my risk score, and which gene changes were found?
  • Do I need treatment now, or can we monitor my blood counts?
  • Am I a candidate for a stem cell transplant, and should I be referred to a transplant centre?
  • What signs should make me call the hospital straight away?
  • Is there a clinical trial I could join?

Bringing a family member or friend to appointments, and keeping a list of your blood results, can help you follow how the disease is changing.

Resources

  1. Khoury, J.D. et al. (2022) ‘The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms’, Leukemia, 36(7), pp. 1703-1719.
  2. Orazi, A. et al. (2023) ‘International Consensus Classification for myeloid neoplasms at-a-glance’, American Journal of Hematology, 98(1), pp. 6-10.
  3. Patnaik, M.M. and Tefferi, A. (2024) ‘Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management’, American Journal of Hematology, 99(6), pp. 1142-1165.
  4. Such, E. et al. (2013) ‘Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia’, Blood, 121(15), pp. 3005-3015.
  5. Elena, C. et al. (2016) ‘Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia’, Blood, 128(10), pp. 1408-1417.
  6. Padron, E. et al. (2015) ‘An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies’, Blood Cancer Journal, 5(7), e333.
  7. Duchmann, M. et al. (2018) ‘Prognostic role of gene mutations in chronic myelomonocytic leukemia patients treated with hypomethylating agents’, EBioMedicine, 31, pp. 174-181.
  8. National Cancer Institute (2026) Myelodysplastic/Myeloproliferative Neoplasms Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/myeloproliferative/hp/mds-mpd-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.